American Diabetes Association--63rd Scientific Sessions. Clinical data. 13-17 June 2003, New Orleans, LA, USA.
Evans
Liz
L
Thomson Current Drugs, Middlesex House, 34-42 Cleveland Street, London W1T 4JE, UK. liz.evans@current-drugs.com
D000284:Administration, Oral; D000682:Amyloid / Q000627:therapeutic use; D003920:Diabetes Mellitus / Q000188:drug therapy* / Q000503:physiopathology; D003929:Diabetic Neuropathies / Q000188:drug therapy; D004338:Drug Combinations; D016503:Drug Delivery Systems; D005632:Fructose / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D007211:Indoles / Q000627:therapeutic use; D007328:Insulin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D061268:Insulin Lispro; D058228:Islet Amyloid Polypeptide; D008301:Maleimides / Q000627:therapeutic use; D018696:Neuroprotective Agents / Q000627:therapeutic use; D000077236:Topiramate
D000682:Amyloid; D004338:Drug Combinations; C473734:Exubera; D007004:Hypoglycemic Agents; D007211:Indoles; D007328:Insulin; D061268:Insulin Lispro; D058228:Islet Amyloid Polypeptide; D008301:Maleimides; D018696:Neuroprotective Agents; D000077236:Topiramate; D005632:Fructose; C099154:ruboxistaurin; C105254:pramlintide